Improved humoral immunogenicity with mRNA-1273 versus BNT162b2 as third vaccine dose among solid organ transplant recipients seronegative after two BNT162b2 doses

Clin Transplant. 2022 Aug;36(8):e14738. doi: 10.1111/ctr.14738. Epub 2022 Jun 14.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 2019-nCoV Vaccine mRNA-1273
  • Antibodies, Viral
  • BNT162 Vaccine
  • Humans
  • Influenza Vaccines*
  • Organ Transplantation* / adverse effects
  • Transplant Recipients

Substances

  • Antibodies, Viral
  • Influenza Vaccines
  • 2019-nCoV Vaccine mRNA-1273
  • BNT162 Vaccine